Evidence map›Paper›PMID 30704519›Full record

ArticleAlzheimer's research & therapy2019

Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease.

Omar A Halawa, Jennifer R Gatchel, Rebecca E Amariglio, Dorene M Rentz, Reisa A Sperling, Keith A Johnson, Gad A Marshall, Alzheimer’s Disease Neuroimaging Initiative

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Alzheimer's research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 55 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Omar A HalawaHarvard Medical School, Boston, MA, 02115, USA.
Jennifer R GatchelHarvard Medical School, Boston, MA, 02115, USA.
Rebecca E AmariglioHarvard Medical School, Boston, MA, 02115, USA.
Dorene M RentzHarvard Medical School, Boston, MA, 02115, USA.
Reisa A SperlingHarvard Medical School, Boston, MA, 02115, USA.
Keith A JohnsonHarvard Medical School, Boston, MA, 02115, USA.
Gad A MarshallHarvard Medical School, Boston, MA, 02115, USA. gamarshall@partners.org.
Alzheimer’s Disease Neuroimaging Initiative
Brigham and Women's Hospital · USHarvard University · US

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Depressive symptoms in the pathogenesis of preclinical Alzheimer's DiseaseK23AG058805 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI GATCHEL, JENNIFER ROSE · 2018 to 2022
$992k
NIA NIH HHS K23 AG058805NIA NIH HHS U01 AG024904U.S. Department of Defense W81XWH-12-2-0012
6 · The paper itself

Abstract

backgroundA decline in instrumental activities of daily living (IADL) correlates with the progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia and has been associated with frontal and parietal hypometabolism, lower cerebrospinal fluid amyloid β

objectiveTo investigate the association between IADL impairment and in vivo regional cerebral tau and cortical amyloid deposition across clinically normal (CN) elderly, MCI, and AD dementia.

methodsFifty-one CN elderly, 30 MCI, and 9 AD dementia participants of the Alzheimer's Disease Neuroimaging Initiative (ADNI) underwent assessment of regional tau deposition with flortaucipir (FTP) positron emission tomography (PET). An aggregate of cortical amyloid burden was assessed by florbetapir PET. IADL were assessed using the Functional Activities Questionnaire (FAQ). Tau regions with unadjusted correlations of p ≤ 0.006 (Bonferroni correction) with FAQ were used to evaluate the cross-sectional association between FAQ (dependent variable) and regional cerebral tau deposition, amyloid burden, and tau-amyloid interaction in separate general linear regression models with backward elimination. Covariates included age, American National Adult Reading Test (AMNART) intelligence quotient (IQ), and Rey Auditory Verbal Learning Test (RAVLT) total learning.

resultsUnadjusted correlations between FAQ and tau in the entorhinal cortex (EC) and inferior temporal cortex (IT) survived Bonferroni correction. FAQ was associated with the tau-amyloid interaction, such that in participants with greater amyloid burden, greater IADL impairment was associated with greater regional tau (EC tau × amyloid: partial r (pr) = 0.47, p < 0.001; IT tau × amyloid: pr = 0.54, p < 0.001). Significant associations were found when these regression models were repeated in symptomatic participants alone but not among CN participants.

conclusionsGreater medial and inferior temporal tau and cortical amyloid burden were associated with greater IADL impairment in AD. Further elucidation of the biomarkers underlying the functional decline will allow for the early identification of individual at risk of disease progression.

Indexed as

Activities of Daily LivingAgedAged, 80 and overAlzheimer DiseaseAmyloidCognitive DysfunctionCohort StudiesFemaleHumansLongitudinal StudiesMagnetic Resonance ImagingMaleNeuropsychological TestsPositron-Emission Tomographytau ProteinsTemporal LobeAmyloidMAPT protein, humantau ProteinsAlzheimer’s diseaseAmyloidEntorhinal cortexInferior temporal cortexInstrumental activities of daily livingMild cognitive impairmentPositron emission tomographyTau

Identifiers

PMID30704519
PMCPMC6357436
OpenAlexW2915228783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.